Keith T. Flaherty, MD

Publications

Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J.Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma.Clin Cancer Res. 2011 Apr 1;17(7):1684-91.
21325067
Flaherty KT.Is It Good or Bad to Find a BRAF Mutation?.J Clin Oncol. 2011 Apr 1;29(10):1229-30.
21343552
Puzanov I, Burnett P, Flaherty KT.Biological challenges of BRAF inhibitor therapy.Mol Oncol. 2011 Feb 16.
21393075
Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ.Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.Cancer Chemother Pharmacol. 2011
21350850
Flaherty KT.Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress.Pigment Cell Melanoma Res. 2011 Feb;24(1):107-9.
21232025
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE,
21107320
Puzanov I, Flaherty KT.Targeted molecular therapy in melanoma.Seminars In Cutaneous Medicine And Surgery. 2010 Sep;29(3):196-201.
21051014
Flaherty KT.Narrative review: BRAF opens the door for therapeutic advances in melanoma.Ann Intern Med. 2010 Nov 2;153(9):587-91. Review.
21041578
Flaherty KT, McArthur G.BRAF, a target in melanoma: implications for solid tumor drug development.Cancer. 2010 Nov 1;116(21):4902-13.
20629085
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Ko
20823850
Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, Leachman S, Messina J, O'Day S, Ribas A, Sondak V.Meeting report from the Third Global Workshop on Melanoma.Pigment Cell Melanoma Res. 2010 Oct;23(5):e1-7.
20718940
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.Inhibition of mutated, activated BRAF in metastatic melanoma.N Engl J Med. 2010 Aug 26;363(9):809-19.
20818844
Flaherty KT, Puzanov I.Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.Biochem Pharmacol. 2010 Sep 1;80(5):638-46. Review.
20382128
Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA.Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.Cancer Res. 2010 J
20551059
Flaherty KT, Hodi FS, Bastian BC.Mutation-driven drug development in melanoma.Curr Opin Oncol. 2010 May;22(3):178-83. Review.
20401974
Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G.Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.Ca
20386909
Ji Z, Flaherty KT, Tsao H.Molecular therapeutic approaches to melanoma.Mol Aspects Med. 2010 Apr;31(2):194-204. Review.
20176049
Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM.Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.Lancet Oncol. 2010 Apr;11(4):373-82. Review.
20171141
Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM.Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.Hum Pathol. 2010 Mar;41(3):375-84.
20004943
Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR.Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.Invest New Drugs.
20016927
Flaherty KT.Where does the combination of sorafenib and interferon in renal cell carcinoma stand?.Cancer. 2010 Jan 1;116(1):4-7.
19890962
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK.Final version of 2009 AJCC mela
19917835
Flaherty KT, Brose MS.Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.Clin Cancer Res. 2009 Dec 15;15(24):7749.
20008857
Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, O'Dwyer PJ, Flaherty KT.Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Bra
19996224
Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK.Meeting report: consensus from the
19659612
Flaherty KT, Smalley KS.Preclinical and clinical development of targeted therapy in melanoma: attention to schedule.Pigment Cell Melanoma Res. 2009 Oct;22(5):529-31.
19619259
Smalley KS, Flaherty KT.Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.Future Oncol. 2009 Aug;5(6):775-8.
19663727
Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH.Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in pati
19549767
Smalley KS, Nathanson KL, Flaherty KT.Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.Cancer Res. 2009 Apr 15;69(8):3241-4. Review.
19351826
Jilaveanu L,Zito C,Lee SJ,Nathanson KL,Camp RL,Rimm DL,Flaherty KT,Kluger HM.Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.Clin Cancer Res. 2009 Feb 1;15(3):1076-85.
19188183
Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL.HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.Cancer Cell. 2
19061835
Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL.Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.Mol C
18790768
Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ.A phase I trial of the oral, multikinase inhibitor so
18676756
Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL.Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.Cancer Res. 2008 Jul 15;68(14)
18632627
Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ.Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.Cancer Biol Ther. 2008 Apr;7(4):496-501.
18219225
Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.Clinical activity and immune modulation in cancer patients treated with CP-
17327609
Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD, Spitz FR.HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.Cancer Res. 2007 Feb 1;67(3):1221-7.
17283158
Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M.An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
17210701
McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM.Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.Clin Cancer Res. 2006 Jun 15;12(12):38
16778114
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.Phase II placebo-controlled randomized discontinuation trial of sorafenib in
16636341
Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M.Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.Mol Cancer Ther. 2006 May;5(5):1136-44.
16731745
Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ.Mechanisms of hypertension associated with BAY 43-9006.J Clin Oncol. 2006 Mar 20;24(9):1363-9.
16446323

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Keith T. Flaherty, MD Publications Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J.Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma.Clin Cancer Res. 2011 Apr 1;17(7):1684-91. 21325067 Flaherty KT.Is It Good or Bad to Find a BRAF Mutation?.J Clin Oncol. 2011 Apr 1;29(10):1229-30. 21343552 Puzanov I, Burnett P, Flaherty KT.Biological challenges of BRAF inhibitor therapy.Mol Oncol. 2011 Feb 16. 21393075 Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ.Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.Cancer Chemother Pharmacol. 2011 21350850 Flaherty KT.Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress.Pigment Cell Melanoma Res. 2011 Feb;24(1):107-9. 21232025 Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, 21107320 Puzanov I, Flaherty KT.Targeted molecular therapy in melanoma.Seminars In Cutaneous Medicine And Surgery. 2010 Sep;29(3):196-201. 21051014 Flaherty KT.Narrative review: BRAF opens the door for therapeutic advances in melanoma.Ann Intern Med. 2010 Nov 2;153(9):587-91. Review. 21041578 Flaherty KT, McArthur G.BRAF, a target in melanoma: implications for solid tumor drug development.Cancer. 2010 Nov 1;116(21):4902-13. 20629085 Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Ko 20823850 Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, Leachman S, Messina J, O'Day S, Ribas A, Sondak V.Meeting report from the Third Global Workshop on Melanoma.Pigment Cell Melanoma Res. 2010 Oct;23(5):e1-7. 20718940 Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.Inhibition of mutated, activated BRAF in metastatic melanoma.N Engl J Med. 2010 Aug 26;363(9):809-19. 20818844 Flaherty KT, Puzanov I.Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.Biochem Pharmacol. 2010 Sep 1;80(5):638-46. Review. 20382128 Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA.Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.Cancer Res. 2010 J 20551059 Flaherty KT, Hodi FS, Bastian BC.Mutation-driven drug development in melanoma.Curr Opin Oncol. 2010 May;22(3):178-83. Review. 20401974 Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G.Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.Ca 20386909 Ji Z, Flaherty KT, Tsao H.Molecular therapeutic approaches to melanoma.Mol Aspects Med. 2010 Apr;31(2):194-204. Review. 20176049 Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM.Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.Lancet Oncol. 2010 Apr;11(4):373-82. Review. 20171141 Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM.Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.Hum Pathol. 2010 Mar;41(3):375-84. 20004943 Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR.Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.Invest New Drugs. 20016927 Flaherty KT.Where does the combination of sorafenib and interferon in renal cell carcinoma stand?.Cancer. 2010 Jan 1;116(1):4-7. 19890962 Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK.Final version of 2009 AJCC mela 19917835 Flaherty KT, Brose MS.Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.Clin Cancer Res. 2009 Dec 15;15(24):7749. 20008857 Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, O'Dwyer PJ, Flaherty KT.Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Bra 19996224 Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK.Meeting report: consensus from the 19659612 Flaherty KT, Smalley KS.Preclinical and clinical development of targeted therapy in melanoma: attention to schedule.Pigment Cell Melanoma Res. 2009 Oct;22(5):529-31. 19619259 Smalley KS, Flaherty KT.Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.Future Oncol. 2009 Aug;5(6):775-8. 19663727 Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH.Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in pati 19549767 Smalley KS, Nathanson KL, Flaherty KT.Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.Cancer Res. 2009 Apr 15;69(8):3241-4. Review. 19351826 Jilaveanu L,Zito C,Lee SJ,Nathanson KL,Camp RL,Rimm DL,Flaherty KT,Kluger HM.Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.Clin Cancer Res. 2009 Feb 1;15(3):1076-85. 19188183 Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL.HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.Cancer Cell. 2 19061835 Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL.Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.Mol C 18790768 Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ.A phase I trial of the oral, multikinase inhibitor so 18676756 Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL.Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.Cancer Res. 2008 Jul 15;68(14) 18632627 Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ.Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.Cancer Biol Ther. 2008 Apr;7(4):496-501. 18219225 Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.Clinical activity and immune modulation in cancer patients treated with CP- 17327609 Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD, Spitz FR.HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.Cancer Res. 2007 Feb 1;67(3):1221-7. 17283158 Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M.An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. 17210701 McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM.Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.Clin Cancer Res. 2006 Jun 15;12(12):38 16778114 Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.Phase II placebo-controlled randomized discontinuation trial of sorafenib in 16636341 Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M.Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.Mol Cancer Ther. 2006 May;5(5):1136-44. 16731745 Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ.Mechanisms of hypertension associated with BAY 43-9006.J Clin Oncol. 2006 Mar 20;24(9):1363-9. 16446323
Site Map Site Feedback Web Privacy Policy